ANRS 12372 MODERATO Study

HIV-1-infection Clinical Trial

— MODERATO  

Official title:

Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV) or Dolutegravir + Lamivudine + Tenofovir (DTG+3TC+TDF) in West and Central African HIV-1 Infected Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04022967
• Other study ID #: ANRS 12372 MODERATO
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: September 21, 2020
• Est. completion date: February 5, 2025

Study information

• Verified date: May 2023
• Source: ANRS, Emerging Infectious Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

MODERATO is a phase III, open-label, randomized, multicenter, non-inferiority trial conducted in West and Central Africa (Cameroon, Côte d'Ivoire, Burkina Faso).

HIV-1 infected adults receiving first line ART with TDF+XTC+EFV or DTG+XTC+TDF virologically suppressed will be recruited and followed during 100 weeks.

The objective is to assess the non-inferiority of a strategy consisting of switching to a dual maintenance therapy (DTG+3TC or ATV/r+3TC), comparing to WHO standard first line regimen (TDF+3TC+EFV or DTG+3TC+TDF), in terms of virological success at 96 weeks

Description:

In HIV-1 infected adults receiving first line ART with TDF+XTC+EFV or DTG+XTC+TDF virologically suppressed (viral load < detection limit of the technique used) for at least two years: to assess the non-inferiority of a strategy consisting of switching to a dual maintenance therapy (DTG+ 3TC or ATV/r+3TC), comparing to WHO standard first line regimen (TDF+3TC+EFV or DTG+3TC+TDF), in terms of virological success at 96 weeks, in Cameroon, Côte d'Ivoire and Burkina Faso.

This is a trial including two strategies (dual maintenance therapy and triple reference therapy) and three ART regimens (DTG+3TC and ATV/r+3TC used in the maintenance strategy and TDF+3TC+EFV/ DTG+3TC+TDF used in the reference strategy).

The primary analysis will compare the two strategies. Secondary analyses will compare the three ART regimens two by two.

In order to make these secondary analyses possible, participants will be randomly assigned, at inclusion, to each of the three ART regimens (arm 1: DTG+3TC; arm 2: ATV/r+3TC; arm 3: TDF+3TC+EFV / DTG+3TC+TDF). The maintenance strategy will include arm 1 and 2. The reference strategy will include arm 3

Number of participants : 480 (160 in each ART regimen, ie 320 in the dual maintenance therapy strategy and 160 in the triple therapy reference strategy)

The primary endpoint is treatment success, as defined by using the FDA snapshot algorithm :

patients who are still continuing the assigned strategy and whose last available plasma HIV-1 RNA in the the window analysis (90 to 102 weeks) is <50 copies/ml at the end of the window analysis (90 to 102 weeks)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 480
• Est. completion date: February 5, 2025
• Est. primary completion date: February 5, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-1 infection

• Age of legal majority

• CD4 > 200 cells/mm3 at pre-inclusion

• Start first-line ART with non-nucleotide reverse transcriptase inhibitors including TDF+XTC+EFV for at least two years without a past history of virological failure, OR

• Be on TDF+XTC+EFV for at least two years then DTG+XTC+TDF without a past history of virological failure, OR

• Be on DTG+XTC+TDF (1st line regimen) for at least two years without a past history of virological failure

• Absence of past history of virological failure (viral load above the threshold corresponding to the test used); two blips between 50 and 200 copies/ml are allowed.

• At least 2 consecutive HIV-1 RNA < 50 copies/ml within past 2 years, including HIV-1 RNA at pre-inclusion

• Women with pregnancy potential are required to use an effective contraceptive method throughout the study follow up.

• Signed informed consent

Exclusion Criteria:

• HIV-2 infection or HIV-1+2 infection

• CD4 nadir <100 cells/mm3

• Chronic Hepatitis B (HBs Ag positive in the pre-inclusion balance)

• Ongoing active Tuberculosis

• Ongoing severe opportunistic infection

• Ongoing chemotherapy or immunotherapy

• Grade > 2 hemoglobin, neutrophil or platelet disorder

• ALT= 3 times the upper limit of normal value

• Creatinine clearance < 50 ml/min (CKD-EPI)

• Allergy to a trial drugs or drug component

• Ongoing pregnancy or Refusal of contraception

• Patient at risk of non-compliance

• Ongoing treatment with a drug that should not be associated with one of the drugs used in the study (cf appendix E page 77)

• Any symptoms or biological findings suggestive of a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or other medical conditions that may interfere with the interpretation of test results or jeopardize the health of patients

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Drug:
• dolutegravir
One daily tablet (50mg) during 96 weeks
• atazanavir boosted with ritonavir
One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
• tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir
One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
• Lamivudine
One daily tablet (300mg) during 96 weeks

Locations

Country	Name	City	State
Burkina Faso	Hôpital de jour, Service des maladies infectieuses, CHU Sourô Sanou	Bobo-Dioulasso
Burkina Faso	Service de médecine interne, CHU Yalgado Ouédraogo	Ouagadougou
Cameroon	Service des Maladies Infectieuses, Hôpital du jour, Hôpital Central	Yaoundé
Côte D'Ivoire	Centre de Prise en Charge et de Formation (CePReF), Association ACONDA	Abidjan
Côte D'Ivoire	Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville	Abidjan

Sponsors (2)

Lead Sponsor	Collaborator
ANRS, Emerging Infectious Diseases	Mylan Laboratories

Countries where clinical trial is conducted

Burkina Faso,  Cameroon,  Côte D'Ivoire, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The treatment success, as defined by using the FDA snapshot algorithm	Success : The proportion of patients who are still continuing the assigned strategy and whose last available plasma HIV-1 RNA in the the window analysis is <50 copies/ml at the end of the window analysis.; Failure : patients who have discontinued the assigned strategy or whose last available plasma HIV-1 RNA in the window analysis (90 to 102 weeks) is = 50 copies/ml or with no available HIV-1 RNA in the window analysis	90 to 102 weeks
Secondary	Failure combined endpoint	Percentage of participants who reach the following combined endpoint : "new drug-resistant resistance mutations observed", "decline of at least 20% in creatinine clearance" and "occurrence of at least one grade 3-4 neuropsychiatric disorder"	Between Day 0 and Week 96
Secondary	Plasma HIV-1 RNA	Evolution of plasma HIV-1 RNA	Between Day 0 and Week 96
Secondary	Virological success	Evolution of the percentage of participants with virological success (VL< 50 copies/Ml)	Between Day 0 and Week 96
Secondary	CD4 lymphocyte	Evolution of CD4 lymphocyte absolute count and percentage	Between Day 0 and Week 96
Secondary	Virological failure and new resistance mutations	Percentage of participants with virological failure and new resistance mutations	Week 48 and Week 96
Secondary	New HIV-1 drug resistance mutations	Profile of new HIV-1 drug resistance mutations observed in participants with virological failure	Week 48 and Week 96
Secondary	WHO stage 3-4 morbidity	Incidence of WHO stage 3-4 morbidity ( AIDS events and non AIDS severe morbidity)	Between Day 0 and Week 96
Secondary	ANRS grade 3-4 overall morbidity	Incidence of ANRS grade 3-4 overall morbidity (toxicity)	Between Day 0 and Week 96
Secondary	ANRS grade 3-4 renal morbidity	Incidence of ANRS grade 3-4 renal morbidity	Between Day 0 and Week 96
Secondary	ANRS grade 3-4 neurologic morbidity	Incidence of ANRS grade 3-4 neurologic morbidity	Between Day 0 and Week 96
Secondary	ANRS grade 3-4 hepatic morbidity	Incidence of ANRS grade 3-4 hepatic morbidity	Between Day 0 and Week 96
Secondary	Creatinine clearance	Evolution of creatinine clearance	Between Day 0 and Week 96
Secondary	Grade 1,2,3 or 4 renal disorders	Evolution of the percentage of patients with grade 1,2,3 or 4 renal disorders	Between Day 0 and Week 96
Secondary	Grade 1,2,3 or 4 hepatic liver disorders or abnormalities	Evolution of the percentage of patients with grade 1,2,3 or 4 hepatic liver disorders or abnormalities	Between Day 0 and Week 96
Secondary	Grade 1,2,3 or 4 CNS disorders	Evolution of the percentage of patients with grade 1,2,3 or 4 CNS disorders	Between Day 0 and Week 96
Secondary	Bone mineral density	Evolution of bone mineral density measured using CT bone density scan	Between Day 0 and Week 96
Secondary	Adherence to treatment using a self-questionnaire	Evolution of adherence to treatments measured using a self-questionnaire	Between Day 0 and Week 96
Secondary	Life quality	Evolution of quality of life measured using the ProQOL questionnaire	Between Day 0 and Week 96
Secondary	Symptoms	Evolution of symptoms using the "symptoms experienced" questionnaire	Between Day 0 and Week 96
Secondary	ARV drug plasma concentrations in participants with treatment failure	ARV drug plasma concentrations in participants with treatment failure	Between Day 0 and Week 96
Secondary	Switched back to triple therapy	Percentage of patients on dual therapy who switched back to triple therapy	Between Day 0 and Week 96
Secondary	Cost-effectiveness of the 3 ARV strategies	Cost-effectiveness of the 3 ARV strategies	Week 96

External Links

•   Related Info
•   Sponsor site